Gilead Sciences Announces Fourth Quarter and Full Year 2020 Financial Results
Gilead Sciences (Nasdaq: GILD) announced its Q4 and full-year 2020 results, emphasizing the significant role of Veklury in treating hospitalized COVID-19 patients. CEO Daniel O’Day highlighted the company's commitment to addressing various health needs, including HIV and cancer. Gilead is optimistic about growth opportunities in oncology with Trodelvy, while continuing its leadership in antivirals. Overall, the company is positioned for growth as it enters 2021.
- Strong market position with Veklury treating one in two hospitalized COVID-19 patients.
- Positive outlook in oncology with Trodelvy for various cancer types.
- None.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2020.
“Gilead continues to play a central role in the pandemic, with Veklury now treating one in two hospitalized patients in the United States. At the same time, we continue to meet the needs of people living with HIV, cancer, viral hepatitis and other conditions,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences. “As we head into 2021, we have many additional opportunities to help patients, especially in oncology where Trodelvy, for example has the potential to treat a broad range of cancer types. These new opportunities, together with our continued leadership in antivirals put Gilead on a clear path to growth.”
Financial Results
|
|
Three Months Ended |
|
|
|
Twelve Months Ended |
|
|
||||||||||||
|
|
December 31, |
|
|
|
December 31, |
|
|
||||||||||||
(In millions, except percentages, per share amounts) |
|
2020 |
|
2019 |
|
Change |
|
2020 |
||||||||||||
FAQ
What were Gilead Sciences' Q4 2020 earnings results?
What is Gilead's outlook for 2021?
What impact did Veklury have on Gilead's operations in 2020?
How did Gilead perform in the full-year 2020?
